About pulmatrix inc - PULM
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. in April 2003 and is headquartered in Framingham, MA.
PULM At a Glance
Pulmatrix, Inc.
945 Concord Street
Framingham, Massachusetts 01701
| Phone | 1-888-355-4440 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -5,162,000.00 | |
| Sector | Health Technology | Employees | 2 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PULM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.138 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.785 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
PULM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,581,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PULM Liquidity
| Current Ratio | 12.55 |
| Quick Ratio | 12.55 |
| Cash Ratio | 12.426 |
PULM Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -73.313 |
| Return on Equity | -80.928 |
| Return on Total Capital | -135.486 |
| Return on Invested Capital | -80.928 |
PULM Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |